Jacobson Pharma Reports Interim Results with Increased Shareholder Dividends
Jacobson Pharma Corporation Limited reported a 5.4% revenue decrease to HK$766.6 million for the six months ending 30 September 2025. Despite this, profit attributable to shareholders rose by 1.2% to HK$142.0 million. The Board declared an interim dividend of HK4.25 cents per share, a 21.4% increase from the previous year. The stock is rated Hold with a HK$1.50 price target. Jacobson Pharma focuses on generic drugs and proprietary medicines, listed on the Hong Kong Stock Exchange under code 2633.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jacobson Pharma Corporation Limited ( (HK:2633) ) just unveiled an announcement.
Jacobson Pharma Corporation Limited reported its interim results for the six months ended 30 September 2025, showing a revenue decrease of 5.4% to HK$766.6 million compared to the same period in 2024. Despite a decline in revenue and operating profit, the company saw a 1.2% increase in profit attributable to equity shareholders, amounting to HK$142.0 million. The Board declared an interim dividend of HK4.25 cents per share, a 21.4% increase from the previous year, indicating a positive outlook for shareholders.
The most recent analyst rating on (HK:2633) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Jacobson Pharma Corporation Limited stock, see the HK:2633 Stock Forecast page.
More about Jacobson Pharma Corporation Limited
Jacobson Pharma Corporation Limited is a pharmaceutical company incorporated in the Cayman Islands. It operates in the pharmaceutical industry, focusing on the development, production, and distribution of generic drugs and proprietary medicines. The company is listed on the Hong Kong Stock Exchange under the stock code 2633.
Average Trading Volume: 540,971
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.81B
